Rituximab in the treatment of three coexistent neurological autoimmune diseases: Chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 82, Issue 2, 2011, Pages 230-232

  Sadnicka, Anna ^a   Reilly, Mary M ^a   Mummery, Cath ^a,b   Brandner, Sebastian ^a   Hirsch, Nicholas ^a   Lunn, Michael P T ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN; RITUXIMAB; VOLTAGE GATED POTASSIUM CHANNEL;

ARTICLE; ARTIFICIAL VENTILATION; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULOPATHY; COMPUTER ASSISTED TOMOGRAPHY; ELECTROMYOGRAPHY; MORVAN SYNDROME; MUSCLE STRENGTH; MYASTHENIA GRAVIS; MYOKYMIA; NERVE CONDUCTION; PLASMAPHERESIS; POLYRADICULONEUROPATHY; PRIORITY JOURNAL;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MYASTHENIA GRAVIS; NEURAL CONDUCTION; NEUROLOGIC EXAMINATION; PLASMA EXCHANGE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; SYRINGOMYELIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78751522498     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.174888     Document Type: Article

References (13)

1. Diaz-Minera J, Rojas-Garcia R, Gallardo E, et al. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nat Clin Pract Neurol 2007;3:405-10.
2. Morvan A. De la chorée fibrillaire. Gaz Hebd Mèd Chir 1890;27:173-6.
3. Josephs KA, Silber MH, Fealey RD, et al. Neurophysiologic studies in Morvan syndrome. J Clin Neurophysiol 2004;21:440-5.
4. Kleopas A, Elman L, Lang B, et al. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K channels: subunit specificity correlates with clinical manifestation. Brain 2006;129:1570-84. (Pubitemid 43999388)
5. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society. Guideline on Management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2005;10:220-8.
6. The French CIDP Study Group. Recommendations on diagnostic strategies for chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2008;79:115-18.
7. Hart IK, Maddison P, Newsom-Davis J, et al. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 2002;125:1887-95.
8. Dalakas MC. Inhibition of B cell functions, implications for neurology. Neurology 2008;70:2252-60.
9. Kuntzer T. Treatment options for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Rev Neurol 2006;162:539-43.
10. Meyer zu Hörste G, Hartung HP, Kieseier BC. From bench to bedside - experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 2007;3:198-211.
11. Gorson K, Natarajan N, Ropper A, et al. Rituximab treatment in patients with IVIG dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007;35:66-9. (Pubitemid 46052650)
12. Benedetti L, Briani C, Fazio R, et al. Rituximab-treated CIDP: a retrospective study. J Peripher Nerv Syst 2009;14:1-163.
13. Liguori R, Vincent A, Clover L, et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001;124:2417-26.